Angela A. Armstrong

Array ( [id] => 16367822 [patent_doc_number] => 10799557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema [patent_app_type] => utility [patent_app_number] => 16/218016 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 8301 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16218016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15978025 [patent_doc_number] => 10669321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-02 [patent_title] => Retinal capillary regeneration with synthetic norrin protein [patent_app_type] => utility [patent_app_number] => 16/214225 [patent_app_country] => US [patent_app_date] => 2018-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 22 [patent_no_of_words] => 11867 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16214225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14372477 [patent_doc_number] => 20190160151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => MEDICAMENT FOR PREVENTING OR TREATING HEART FAILURE [patent_app_type] => utility [patent_app_number] => 16/198937 [patent_app_country] => US [patent_app_date] => 2018-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16198937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17015253 [patent_doc_number] => 11084880 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Anti-BCMA chimeric antigen receptor [patent_app_type] => utility [patent_app_number] => 16/197565 [patent_app_country] => US [patent_app_date] => 2018-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 107 [patent_no_of_words] => 123734 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16197565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14406875 [patent_doc_number] => 20190169281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => ANGPTL8-BINDING AGENTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/184548 [patent_app_country] => US [patent_app_date] => 2018-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16184548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16141451 [patent_doc_number] => 10703787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema [patent_app_type] => utility [patent_app_number] => 16/182252 [patent_app_country] => US [patent_app_date] => 2018-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 8234 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 218 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16182252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14774941 [patent_doc_number] => 20190262368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => BINDING PROTEINS SPECIFIC FOR LOX1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/179135 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16179135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13957901 [patent_doc_number] => 20190055294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => Compositions Comprising Hypoxia Inducible Factor-1 Alpha and Methods of Using the Same [patent_app_type] => utility [patent_app_number] => 16/176262 [patent_app_country] => US [patent_app_date] => 2018-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16176262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18777866 [patent_doc_number] => 11819542 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Immunotherapeutic method for treating lung cancer by administering a polypeptide comprising an epitope of hZP3 [patent_app_type] => utility [patent_app_number] => 16/760457 [patent_app_country] => US [patent_app_date] => 2018-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 55528 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15784933 [patent_doc_number] => 10626173 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR [patent_app_type] => utility [patent_app_number] => 16/175357 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 30278 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16175357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977679 [patent_doc_number] => 20210221916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY [patent_app_type] => utility [patent_app_number] => 16/759331 [patent_app_country] => US [patent_app_date] => 2018-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13931857 [patent_doc_number] => 20190049444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => Methods of Treating Cardiovascular Diseases and Predicting the Efficacy of Exercise Therapy [patent_app_type] => utility [patent_app_number] => 16/170870 [patent_app_country] => US [patent_app_date] => 2018-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13585 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16170870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14883577 [patent_doc_number] => 10421815 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Anti-CXCR4 antibodies and antibody-drug conjugates [patent_app_type] => utility [patent_app_number] => 16/166830 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 28 [patent_no_of_words] => 57534 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16166830 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19884205 [patent_doc_number] => 12269898 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-08 [patent_title] => Transthyretin immunoglobulin fusions [patent_app_type] => utility [patent_app_number] => 16/753216 [patent_app_country] => US [patent_app_date] => 2018-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 33695 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16753216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837465 [patent_doc_number] => 20190022217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => PHARMACEUTICAL FORMULATIONS AND METHODS OF MAKING THE SAME [patent_app_type] => utility [patent_app_number] => 16/144120 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14747431 [patent_doc_number] => 20190256889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => TIE2 RECEPTOR ACTIVATION FOR GLAUCOMA [patent_app_type] => utility [patent_app_number] => 16/143017 [patent_app_country] => US [patent_app_date] => 2018-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16143017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435751 [patent_doc_number] => 20200353076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES [patent_app_type] => utility [patent_app_number] => 16/648130 [patent_app_country] => US [patent_app_date] => 2018-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76569 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253522 [patent_doc_number] => 20200262896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => MELANIN ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/646994 [patent_app_country] => US [patent_app_date] => 2018-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13790647 [patent_doc_number] => 20190008862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE [patent_app_type] => utility [patent_app_number] => 16/127921 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5889 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16127921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13778009 [patent_doc_number] => 20190002543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => Inflammatory Disease Treatment Composition Including Anti-Myosin Regulatory Light-Chain Polypeptide Antibody [patent_app_type] => utility [patent_app_number] => 16/122903 [patent_app_country] => US [patent_app_date] => 2018-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13593 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16122903 [rel_patent_id] =>[rel_patent_doc_number] =>)